Employees: 2,088
Size SMS Pharmaceuticals (SMSPHARMA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $477M, the 861st largest of 1,066 India companies the cockpit tracks. Shares closed at ₹476.80 on 18 Nov 2026.
Performance Over six months the shares gained 16.2%, against -9.3% for the median peer and +3.8% for the India market (cap-weighted) — 6th highest of 20 in its peer set.
Growth Revenue grew 13.0% over the last twelve months (peer median +9.4%); the operating margin is 15.6% (peer median 10.5%).
Valuation It trades at 42.2× forward earnings against a peer median of 21.3× (most expensive of 6).
Capital Return on invested capital runs 4.8 points below its cost of capital (14.6% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹9.71B | ₹8.83B | ₹7.79B | ₹7.06B | ₹5.20B |
| Revenue growth | — | +13% | +10% | +36% | — |
| Gross profit | ₹2.00B | ₹1.84B | ₹1.53B | ₹1.20B | ₹478M |
| EBITDA | ₹1.92B | ₹1.68B | ₹1.38B | ₹1.15B | ₹535M |
| Net income | ₹1.17B | ₹1.02B | ₹691M | ₹498M | -₹70.6M |
| Free cash flow | n/a | -₹926M | -₹589M | -₹236M | -₹282M |
| Capital expenditure | n/a | ₹1.31B | ₹1.23B | ₹522M | ₹299M |
| Total debt | ₹3.49B | ₹3.65B | ₹3.11B | ₹2.81B | ₹2.54B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SMSPHARMA.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +9.7% | -3.4% | 6th highest of 21 |
| 6-month return | +16.2% | -9.3% | 6th highest of 20 |
| Distance from 52-week high | -10.9% | -38.3% | 5th highest of 21 |
| Revenue growth (TTM) | +13.0% | +9.4% | 9th highest of 20 |
| Operating margin | 15.6% | 10.5% | 5th highest of 19 |
| Forward P/E | 42.2× | 21.3× | most expensive of 6 |
| ROIC minus cost of capital | -4.8 pp | -3.2 pp | 9th lowest of 18 |
| EV / EBITDA | 24.8× | 12.1× | 2nd most expensive of 5 |
| Net debt / EBITDA | 1.6× | 0.2× | most indebted of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SMS Pharmaceuticals SMSPHARMA.NS | India | $477M | +16% | +13% | 16% | 42.2× | n/a | n/a |
| Shanghai Fudan Forward S&T 600624.SS | China | $478M | 0% | -14% | -34% | n/a | n/a | n/a |
| Hansa Biopharma HNSA.ST | Sweden | $479M | +39% | +69% | -190% | n/a | -4.7% | +105.3% |
| Aquestive Therapeutics AQST | United States | $475M | -9% | +13% | -114% | n/a | n/a | n/a |
| REGENXBIO RGNX | United States | $480M | +22% | -5% | -120% | n/a | n/a | n/a |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $481M | -8% | +23% | -61% | n/a | n/a | n/a |
| YungShin Global 3705.TW | Taiwan | $472M | +5% | -5% | 15% | n/a | -3.8% | +0.7% |
| ChengDa PharmaCeuticals 301201.SZ | China | $472M | -47% | +27% | -9% | n/a | n/a | n/a |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $469M | +45% | -16% | 30% | 24.9× | 24.8% | +126.7% |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $486M | -21% | -1% | 10% | 18.2× | n/a | n/a |
| Evolus EOLS | United States | $468M | +7% | +14% | -5% | 28.5× | n/a | n/a |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $487M | -29% | +32% | 17% | n/a | 3.3% | -1.1% |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $468M | -32% | -4% | -11% | n/a | n/a | n/a |
| Capricor Therapeutics CAPR | United States | $467M | -70% | -100% | n/a | n/a | n/a | n/a |
| Kwality Pharmaceuticals KPL.NS | India | $467M | +110% | +48% | 22% | n/a | n/a | n/a |
| Newland Pharmaceutical 301277.SZ | China | $488M | -22% | +9% | 11% | n/a | 8.9% | +9.1% |
| Hainan Shuangcheng Pharmaceuticals 002693.SZ | China | $465M | -28% | +40% | 13% | n/a | 44.1% | +1.0% |
| BlossomHill Therapeutics BLSM | United States | $464M | n/a | n/a | n/a | n/a | n/a | n/a |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $491M | -19% | -14% | 12% | 7.3× | -17.2% | +6.3% |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $493M | -20% | -4% | 18% | n/a | 5.9% | -4.1% |
| Aarti Drugs AARTIDRUGS.NS | India | $494M | +34% | +15% | 11% | 21.3× | 22.1% | +3.5% |